Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
39,767,515
-
Share change
-
+9,950,316
-
Total reported value
-
$218,419,138
-
Price per share
-
$5.51
-
Number of holders
-
48
-
Value change
-
+$54,884,349
-
Number of buys
-
28
-
Number of sells
-
13
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q1 2017
As of 31 Mar 2017,
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) was held by
48 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
39,767,515 shares.
The largest 10 holders included
NEA Management Company, LLC, Capital World Investors, FMR LLC, ORBIMED ADVISORS LLC, Tekla Capital Management LLC, QVT Financial LP, Hillhouse Capital Management, Ltd., BAILLIE GIFFORD & CO, AXA, and Rock Springs Capital Management LP.
This page lists
48
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.